Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M
Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M
Valneva預計2024年的總收入爲1.7億至1.9億歐元，研發投資在6000萬至7500萬歐元之間
2024 financial guidance confirmed
2024 年財務指引已確認
- Expected total revenues between €170 million and €190 million, including:
- €160 million to €180 million of sales driven by growth of Valneva's proprietary products
- 預計總收入在1.7億歐元至1.9億歐元之間，包括：
- 在Valneva專有產品的增長推動下，銷售額爲1.6億至1.8億歐元
- Expected R&D investments between €60 million and €75 million, mostly dedicated to ongoing chikungunya development activities, the Zika trial and advancement of pre-clinical programs
- Expected Other income between €100 million and €110 million, reflecting €95 million in proceeds from the PRV sale
- 預計研發投資在6000萬歐元至7500萬歐元之間，主要用於正在進行的基孔肯雅熱開發活動、寨卡試驗和臨床前項目的推進
- 預計其他收入介於1億歐元至1.1億歐元之間，反映了9,500萬歐元的PRV出售收益